Cancer is a complex disease driven by somatic mutations accumulating within a cell's genome.  Advances in genomics have significantly improved our understanding of the genetic basis of cancer heterogeneity, revealing distinct driver mutations and pathways contributing to tumorigenesis. This knowledge underpins the development of personalized medicine, moving beyond a 'one-size-fits-all' approach to cancer treatment.  Next-generation sequencing (NGS) technologies enable comprehensive genomic profiling, identifying specific mutations that dictate therapeutic strategies. For instance, identifying EGFR mutations in lung cancer guides the use of targeted tyrosine kinase inhibitors, while detection of specific BRCA mutations in breast or ovarian cancer informs the use of PARP inhibitors.  Furthermore, understanding the tumor microenvironment's genetic influence through analysis of circulating tumor DNA (ctDNA) and immune checkpoint biomarkers enhances treatment efficacy and allows for real-time monitoring of treatment response and disease recurrence. However, challenges remain, including the interpretation of complex genomic data, the identification of actionable mutations, and equitable access to these advanced technologies. Future research should focus on integrating multi-omics data to refine personalized cancer care and improve patient outcomes.